Sign up Australia
Proactive Investors - Run By Investors For Investors

ImpediMed begins lymphoedema study using its health device

The aim is to detect lymphoedema at the earliest possible point.
ImpediMed begins lymphoedema study using its health device
Accurate measurement allows early detection and intervention

ImpediMed (ASX:IPD) has commenced enrolment in the first planned clinical study of its “SOZO” device for lymphoedema, a condition that causes swelling in the body's tissues.

SOZO uses bioimpedance spectroscopy (BIS) technology to manage and monitor a person’s fluid status, body composition and hydration in a clinical or at-home setting.

Lymphoedema is a leading post-surgical complication for many breast cancer patients and significantly impacts quality of life.

The accurate measurement of fluid in limbs by SOZO allows early detection and intervention.

Importantly, the aim of this study is to determine the best practices for at-home lymphoedema monitoring.

The study is being led by Louise Koelmeyer, the Lymphoedema Program Manager of Macquarie University Hospital’s ALERT (Australian Lymphoedema Education, Research & Treatment) program.

The ALERT team aims to optimise positive outcomes for people living with lymphoedema through excellence in assessment and management of the condition along the continuum.

Macquarie University has recognised the potential for SOZO to improve the way patients are monitored and has initiated this study to help establish how the at-home program is best implemented.

The aim is to detect lymphoedema at the earliest possible point in its development when its progression can be stopped or even reversed.

View full IPD profile View Profile

ImpediMed Timeline

Newswire
November 14 2013

Related Articles

picture of cannabis plants
March 24 2018
Control of the supply chain offers operational advantages and financial benefits.
lab
March 15 2018
Amryt's lead drug candidate, AP101, is a potential treatment for epidermolysis bullosa, a rare genetic skin disorder for which there is currently no approved treatment
researcher filling a vial
April 24 2018
2018 is shaping up to be a crucial year for the company's drug pipeline

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use